Skip to main content
Equibles

NVS · Novartis AG · Earnings Call Transcripts & Audio

Track NVS — free

Use NVS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NVS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$140.77 -4.94 (-3.39%)
Rebalance outlook locked
Market Cap
$276.48B
Shares
1.90B
Volume · Sep 30 3.06M Avg daily vol (3M) 1.93M

Novartis AG Earnings Call Transcripts

Quarterly earnings calls for Novartis AG (NVS), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Pull transcripts and briefs through the earnings call transcript API or MCP →
Earnings call
FY25 · Q4
2025-12-31
Novartis AG (NVS) Q4 2025 Earnings Call Transcript
Confident tone Kisqali growth and peak sales outlook Remibrutinib and pelabresib pipeline progress Avidity acquisition / SG&A and margin dilution
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-09-30
Novartis AG (NVS) Q3 2025 Earnings Call Transcript
Confident tone Full-year 2025 guidance and margin outlook Generic erosion of legacy brands Late-stage pipeline and approvals
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-06-30
Novartis AG (NVS) Q2 2025 Earnings Call Transcript
Confident tone Priority brands momentum Topline and margin growth Entresto generic risk and IP defense
Diluted EPS
$2.06
▲ 29.6% YoY
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-03-31
Novartis AG (NVS) Q1 2025 Earnings Call Transcript
Confident tone Kisqali momentum in metastatic and early breast cancer Pluvicto PSMAfore launch and radioligand expansion Pipeline and regulatory milestones
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2024-12-31
Novartis AG (NVS) Q4 2024 Earnings Call Transcript
Confident tone Key growth brands (Cosentyx, Kesimpta, Kisqali) Pluvicto and radioligand therapy (RLT) pipeline Pipeline readouts and innovation momentum
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-09-30
Novartis AG (NVS) Q3 2024 Earnings Call Transcript
Confident tone Kisqali early breast cancer launch Entresto growth and loss of exclusivity IRA legislation and siRNA policy
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-06-30
Novartis AG (NVS) Q2 2024 Earnings Call Transcript
Confident tone Growth drivers and brand momentum Pluvicto / radioligand therapy Remibrutinib manufacturing delay
Diluted EPS
$1.59
▲ 43.2% YoY
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
Novartis AG (NVS) Q1 2024 Earnings Call Transcript
Confident tone Leqvio geographic ramp Cosentyx and new indications Kisqali and early breast cancer
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q4
2023-12-31
Novartis AG (NVS) Q4 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-K
Earnings call
FY23 · Q3
2023-09-30
Novartis AG (NVS) Q3 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Earnings call
FY23 · Q1
2023-03-31
Novartis AG (NVS) Q1 2023 Earnings Call Transcript
Results not yet reported
Audio Transcript Slides 8-K10-Q
Showing 1–11 of 11 earnings calls
Key facts CIK 1114448 CUSIP 66987V109 13F (30d) 36 filings 20 filers Visit website Investor relations